Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Therapie ; 73(3): 231-236, 2018.
Article in French | MEDLINE | ID: mdl-29146040

ABSTRACT

OBJECTIVE: Study the therapeutic maintenance, efficacy and reasons for tocilizumab stop in daily practice. PATIENTS AND METHODS: A monocentric, retrospective study of patients treated for rheumatoid arthritis who received at least one TCZ infusion between January 2009 and December 2015. Therapeutic maintenance was evaluated using the Kaplan-Meier method. The efficacy of TCZ was measured by DAS28 and the EULAR response. Reasons for stopping and new treatment lines were also collected. RESULTS: Of the 88 patients (83% women and 17% men) who were included, the mean age was 54±12.5 years. There were 75% positive rheumatoid factors and 76% positive anti-CCP. The mean duration of the follow-up was 31 months. TCZ was used as monotherapy in 24 patients (27%). Before the introduction of TCZ, the mean DAS28 was 5.07±1.32. The EULAR response at 1 year in patients still under treatment (n=63) was obtained in 59 (93.7%) patients, 46 good responders and 13 moderate responders. Therapeutic maintenance was 82.9%, 72.5%, 68.7% and 57.2%, respectively, at 12, 24, 36 and 54 months. Twenty-eight patients (32%) followed TCZ, 10 for adverse events and 14 for ineffectiveness. Abatacept was the main new therapeutic line. CONCLUSION: The therapeutic maintenance of TCZ in common practice over a long period of follow-up is similar to pivotal studies. Efficacy data are reassuring in the long-term.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Adult , Aged , Female , Hospitals, University , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Retrospective Studies , Treatment Outcome
3.
Therapie ; 71(3): 281-6, 2016 Jun.
Article in French | MEDLINE | ID: mdl-27235651

ABSTRACT

PURPOSE: Evaluation of effectiveness and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure. METHODS: We conducted a retrospective and monocentric study. The evaluation of articular and cutaneous effectiveness by the patient was made with numeric scale and satisfaction scale and by the physician during a rhumatological-dermatological consultation. The safety was analyzed by collecting the adverse effects. RESULTS: Nine patients with anti-TNF failure were included. Five of them stopped the treatment because of severe adverse effects. The mean duration treatment of ustekinumab was 24 months. Articular and cutaneous effectiveness were respectively 4.4/10 and 6.7/10. Two thirds of the patients were "satisfied" and one third could stop any analgesic treatment. The mean PASI score decreased from 8.4 to 1.7 after 3 months treatment. Only minor adverse effects were collected and there were no recidivism of the adverse effects observed with anti-TNFα. CONCLUSION: Ustekinumab is an effective and safe alternative for patients with anti-TNFα failure in psoriatic arthritis.


Subject(s)
Arthritis, Psoriatic/drug therapy , Dermatologic Agents/therapeutic use , Patient Satisfaction , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Ustekinumab/therapeutic use , Adult , Aged , Arthritis, Psoriatic/psychology , Dermatologic Agents/adverse effects , Female , Hand Dermatoses/chemically induced , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Retrospective Studies , Treatment Failure , Ustekinumab/adverse effects
5.
Joint Bone Spine ; 79(4): 409-11, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22405857

ABSTRACT

A patient was diagnosed with discitis and sacroiliitis due to Mycobacterium xenopi. He had a history of percutaneous nucleotomy performed 15 years earlier (in 1992) at the Clinique du Sport, Paris, France, during an outbreak of nosocomial M. xenopi infection at that institution. In 1997, magnetic resonance imaging performed as part of the routine follow-up program for patients who had surgery at the Clinique du Sport during the outbreak was not interpreted as indicating discitis; this assessment was confirmed by our review of the images. Bone and joint infections due to atypical mycobacteria are rare and can develop very slowly. To our knowledge, this is the first reported case of M. xenopi discitis with secondary extension to the sacroiliac joint in an immunocompetent patient.


Subject(s)
Cross Infection/diagnosis , Discitis/diagnosis , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium xenopi , Sacroiliitis/diagnosis , Surgical Wound Infection/microbiology , Antibiotics, Antitubercular/therapeutic use , Antitubercular Agents/therapeutic use , Clarithromycin/therapeutic use , Cross Infection/drug therapy , Cross Infection/microbiology , Discitis/drug therapy , Discitis/microbiology , Disease Outbreaks , Diskectomy, Percutaneous/adverse effects , Drug Therapy, Combination , Ethambutol/therapeutic use , Humans , Immunocompetence , Magnetic Resonance Imaging , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/microbiology , Rifampin/therapeutic use , Sacroiliitis/drug therapy , Sacroiliitis/microbiology , Treatment Outcome
6.
Joint Bone Spine ; 76(4): 401-3, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19481489

ABSTRACT

We report the case of a 48-year-old man who presented with left calf hypertrophy 6 years after an episode of left S1 sciatica related to a herniated disk. Magnetic resonance imaging disclosed muscle hypertrophy. Electromyography showed left S1 radiculopathy with abnormal spontaneous muscle activity. Neurogenic muscle hypertrophy is a rare phenomenon that is chiefly seen when denervation occurs slowly and gradually. The typical patient is a middle-aged man who has a history of S1 radiculopathy. The soleus muscle is the main site of involvement. The pathophysiology is unclear but may involve type I fiber hypertrophy in response to the complex repetitive discharges recorded by electromyography. The natural history of neurogenic muscle hypertrophy is incompletely understood.


Subject(s)
Muscle, Skeletal/innervation , Muscle, Skeletal/pathology , Electromyography , Humans , Hypertrophy/etiology , Hypertrophy/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Radiculopathy/complications
7.
Presse Med ; 36(11 Pt 1): 1527-35, 2007 Nov.
Article in French | MEDLINE | ID: mdl-17662570

ABSTRACT

OBJECTIVE: To assess the efficacy of percutaneous laser disc decompression for patients with radicular pain due to lumbar disc hernia and to identify factors that may predict outcome. METHODS: The study included all patients treated with percutaneous laser disc decompression from May 2003 through May 2005 at Reims University Hospital and the Courlancy Clinic of Reims. Each patient had previous undergone at least six weeks of conventional medical treatment. The same technique, with either a laser diode or Nd: YAG, was used under endoscopic control and with neuroleptanalgesia. They were seen at 1, 3, 6 and 12 months. The principal evaluation criteria were the course of radicular pain, return to work, and need for surgery. RESULTS: We reexamined 149 patients 1 month after the procedure, 135 after 3 months, 102 after 6 months and 59 a year after the procedure. At a month after surgery, radicular pain had decreased by at least half, and sometimes even completely disappeared in 63.1% of patients at 1 month, 66.6% at 3 months, 73.5% at 6 months, and 83.1% at 12 months, while 24%, 50,4%, 61.2%, and 67.3%, respectively, had returned to work. No patient had serious complications. Finally, 45 of the 149 (30.2%) patients chose to have a traditional surgical procedure after percutaneous laser disc decompression. CONCLUSION: Percutaneous laser disc decompression is effective, noninvasive and well tolerated for patients with radicular pain due to lumbar disc hernia.


Subject(s)
Decompression, Surgical/methods , Intervertebral Disc Displacement/complications , Laser Therapy , Low Back Pain/surgery , Adult , Female , Humans , Low Back Pain/etiology , Male , Prospective Studies
8.
Presse Med ; 35(11 Pt 2): 1765-1772, 2006 Nov.
Article in French | MEDLINE | ID: mdl-17086139

ABSTRACT

The clinical forms of tuberculosis that occur during anti-TNFalpha treatment are frequently extrapulmonary or even disseminated and life-threatening. The paradoxical reactions that can occur under appropriate treatment after stopping TNFalpha inhibitors raise the question of an immune restoration phenomenon. Adverse drug reaction reporting and epidemiologic studies, despite their methodological limitations, appear to show an excess risk of tuberculosis. Experimental studies reinforce these data. The French drug agency (Afssaps) has issued guidelines for the prevention and management of tuberculosis occurring under anti-TNFalpha treatment. Analogous guidelines in Spain led to a reduction in the incidence of these cases.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Immunoglobulin G/adverse effects , Tuberculosis/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Adverse Drug Reaction Reporting Systems , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Antitubercular Agents/administration & dosage , Antitubercular Agents/therapeutic use , Clinical Trials as Topic , Drug Therapy, Combination , Etanercept , Female , Follow-Up Studies , Humans , Immunoglobulin G/therapeutic use , Infliximab , Male , Middle Aged , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/isolation & purification , Practice Guidelines as Topic , Radiography, Thoracic , Receptors, Tumor Necrosis Factor/therapeutic use , Retrospective Studies , Risk Factors , Spondylarthritis/drug therapy , Spondylitis, Ankylosing/drug therapy , Time Factors , Tomography, X-Ray Computed , Tuberculosis/drug therapy , Tuberculosis/immunology , Tuberculosis, Miliary/drug therapy
10.
Joint Bone Spine ; 72(6): 544-9, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16226477

ABSTRACT

OBJECTIVE: The objective of this study was to identify prognostic factors in a uniform population of older patients with myeloma. METHODS: Thirty-one study centers in France included 148 patients who were older than 55 years at diagnosis and were followed up until death or for at least 10 years. The following tests were available for all patients: blood cell counts; serum, and urinary protein electrophoresis; and serum levels of creatinine, calcium, beta2 microglobulin (beta2m), lactic dehydrogenase (LDH), and C-reactive protein (CRP). RESULTS: Mean age was 71.9 years, median survival was 34 months, and mean survival was 47 months. In the univariate analysis, factors significantly associated with higher mortality were male gender (odds ratio [OR], 1-2.12), age older than 70 years (OR, 1.10-2.28), serum albumin<30 g/l (OR, 1.16-3.28), serum creatinine>100 micromol/l (OR, 1.34-2.81), beta2m>6 mg/l (OR, 1.78-4), CRP>6 mg/l (OR, 1.44-3.06), hemoglobin<10 g/dl (OR, 1.8-2.23). In the multivariate analysis, only two factors significantly predicted a higher risk of death: beta2m>6 mg/l (OR=2.439 [1.59-3.76]) and CRP>6 mg/l (OR=1.76 [1.18-2.63). beta2m level was >6 mg/l in 41 (27.7%) patients and CRP was >6 mg/l in 61 (43.6%) patients. Other potential prognostic factors such as chromosome 13 deletion were not investigated because they were not available for all study patients. CONCLUSIONS: The strength of this study is the 10-year follow-up in a uniform patient cohort. beta2m and CRP independently predicted the risk of death.


Subject(s)
Multiple Myeloma/mortality , Aged , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , C-Reactive Protein/analysis , Creatinine/blood , Female , Humans , Male , Melphalan/administration & dosage , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Prednisolone/administration & dosage , Prognosis , Risk Factors , beta 2-Microglobulin/blood
11.
Joint Bone Spine ; 72(3): 260-2, 2005 May.
Article in English | MEDLINE | ID: mdl-15850999

ABSTRACT

Tonic dystonia is an underrecognized complication of reflex sympathetic dystrophy syndrome (RSDS) characterized by an increase in muscle tone at the site of injury. Case-reports.- We describe five cases of tonic dystonia complicating RSDS of the lower extremity. There were four women and one man, with a mean age of 52 years. In addition to the typical features of RSDS, the patients had fixed equinovarus of the foot with hyperextension or hyperflexion of the great toe. In two patients, examination after spinal anesthesia showed that the deformity was reducible. Spontaneous resolution of the dystonia occurred in one patient. Another patient failed to experience meaningful improvement after a motor block followed by botulinic toxin injections. In two patients, the same treatment was followed by a slight improvement. Treatment options are still being evaluated in the last patient. Discussion.- Tonic dystonia is an underrecognized complication of RSDS that often develops after a minor injury yet causes prolonged pain and disability. Spread of the dystonia to other sites is not infrequent. The underlying mechanisms remain unclear but may involve dysfunction of the central or peripheral nervous system or psychogenic factors. Suggested treatments include motor block, intrathecal baclofen, sympathetic block, and sympathectomy. However, none of these treatments has been proved effective. Conclusion.- The five cases described here provide useful information on RSDS-associated tonic dystonia, a condition that runs a protracted course and remains difficult to manage.


Subject(s)
Dystonia/physiopathology , Foot Diseases/physiopathology , Foot , Reflex Sympathetic Dystrophy/physiopathology , Adult , Aged , Dystonia/etiology , Dystonia/therapy , Equinus Deformity/etiology , Equinus Deformity/physiopathology , Equinus Deformity/therapy , Female , Foot Diseases/etiology , Foot Diseases/therapy , Humans , Male , Middle Aged , Reflex Sympathetic Dystrophy/complications , Reflex Sympathetic Dystrophy/therapy , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...